articleCancer Immunology ImmunotherapySep 7, 2006GREEN OA

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

FGFrançois GhiringhelliCMCédric MenardPEPierre E. PuigSLSylvain LadoireSRS. Roux

Inserm · Institut Gustave Roussy

PubMed
Indexed incrossrefdoajpubmed

Abstract

No abstract available for this paper.

Citation impact

1,227
total citations
FWCI
14.14
Percentile
100%
References
22
Citations per year

Authors

10

Topics & keywords

Topics
Keywords
  • Cyclophosphamide
  • Cancer research
  • IL-2 receptor
  • Immunotherapy
  • Medicine
  • Immunology
  • Chemoimmunotherapy
  • Regimen
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding